13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MASCC

    Acronym: 

    MASCC

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Early detection, diagnosis, prognosis
    Phase All phases Tumour Stream Solid tumours
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Early detection, diagnosis, prognosis
    Phase All phases
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid tumours
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Predicting febrile neurotropenia occurrence in adult patients treated with chemotherapy for a solid tumour (or a Hodgkin's/ non-Hodgkin's lymphoma) with an expected moderate risk of febrile neutopenia according to published guidelines (10% to 20%): a MASCC survey.

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Not Yet Recruiting